--- title: "史賽克簽署了最終協議，收購 Amplitude Vascular Systems，以將下一代 IVL 技術納入其外周血管產品組合" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/282541498.md" description: "史賽克已簽署一項最終協議，收購 Amplitude Vascular Systems，增強其外周血管產品組合，加入下一代血管內碎石（IVL）技術。此次收購旨在滿足治療鈣化外周動脈疾病的未滿足臨牀需求。IVL 平台利用脈衝二氧化碳生成的壓力波來優化治療效率。該交易需滿足慣例的成交條件，雙方公司將在交易完成之前繼續獨立運營。史賽克首席執行官 Kevin Lobo 強調了此次收購在擴大患者治療選擇方面的重要性" datetime: "2026-04-13T12:00:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282541498.md) - [en](https://longbridge.com/en/news/282541498.md) - [zh-HK](https://longbridge.com/zh-HK/news/282541498.md) --- # 史賽克簽署了最終協議，收購 Amplitude Vascular Systems，以將下一代 IVL 技術納入其外周血管產品組合 Portage, Michigan, April 13, 2026 (GLOBE NEWSWIRE) -- Stryker , a global leader in medical technologies, announced that it has signed a definitive agreement to acquire Amplitude Vascular Systems, Inc. (AVS), a privately held medical technology company developing a next-generation intravascular lithotripsy (IVL) platform designed to treat calcified peripheral arterial disease. The acquisition will strengthen Stryker’s Peripheral Vascular (PV) portfolio by adding revascularization technology. Once cleared for use in applicable markets, the product will complement Stryker’s existing PV offerings and support the company’s strategy to expand its presence in arterial disease treatment. “This acquisition represents an important step in advancing our vision to build a comprehensive peripheral vascular platform and address significant unmet clinical needs,” said Kevin Lobo, Chair and CEO, Stryker. “Combining this innovation with Stryker’s scale and clinical expertise, we believe we can help expand treatment options for physicians and improve care for patients with calcified peripheral arterial disease.” AVS’ technology is designed to use pulsed CO₂-generated pressure waves uniformly delivered through an IVL balloon catheter, to fracture calcium and optimize luminal gain. The platform is designed to enhance catheter deliverability, treatment speed and therapy efficiency. IVL is a fast-growing technology in cardiovascular intervention and is used to treat calcified peripheral and coronary lesions. It is expected to experience strong growth as physicians adopt IVL-based calcium modification in complex procedures. This transaction is subject to customary closing conditions. Stryker and AVS will continue to operate as separate entities and proceed with business as usual until the transaction closes. **About Stryker** Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com. **About** **Amplitude Vascular Systems (****AVS)** Amplitude Vascular Systems (AVS) is a medical device company based in Boston, Mass., focused on treating severely calcified arterial disease. AVS is backed by global investors including BioStar Capital, Cue Growth Partners, and others. It was founded in 2017 by Hitinder Gurm, M.D., Interventional Cardiologist and Chief Clinical Officer at the University of Michigan, and Robert Chisena, Ph.D., Chief Technical Officer at AVS. More information is available at www.avspulse.com. **Contacts** **For investor inquiries:** Jason Beach, Vice President, Finance and Investor Relations at 269-385-2600 or jason.beach@stryker.com **For media inquiries:** Kim Montagnino, Vice President, Chief Communications Officer at 269-385-2600 or kim.montagnino@stryker.com Image: https://www.globenewswire.com/newsroom/ti?nf=OTY4ODEyMiM3NTMwOTIwIzIwMDgzMjg= Image: https://ml.globenewswire.com/media/ZDI0M2FkMjktOTYxOS00ZWI1LWI0MTItZTVjYTFjY2U3OWRmLTEwMTk5MDEtMjAyNi0wNC0xMy1lbg==/tiny/Stryker-Corporation.png Image: Primary Logo Source: Stryker Corporation ( SYK ) ### 相關股票 - [SYK.US](https://longbridge.com/zh-HK/quote/SYK.US.md) - [IHI.US](https://longbridge.com/zh-HK/quote/IHI.US.md) - [XHE.US](https://longbridge.com/zh-HK/quote/XHE.US.md) ## 相關資訊與研究 - [鉅亨速報 - Factset 最新調查：瑞斯邁 RMD-US 的目標價調降至 293.26 元，幅度約 5.4%](https://longbridge.com/zh-HK/news/284257402.md) - [來稿｜美伊戰事外溢網絡空間 香港如何應對數碼主權危機？](https://longbridge.com/zh-HK/news/284334508.md) - [Villere ST Denis J & Co. LLC 出售了史賽克公司（Stryker Corporation）的股票，代碼為$SYK](https://longbridge.com/zh-HK/news/283813470.md) - [Harbour Trust & Investment Management Co 購買了 3,160 股史賽克公司股票，代碼為$SYK](https://longbridge.com/zh-HK/news/283824172.md) - [史賽克 2026 年第一季度財報：有哪些預期](https://longbridge.com/zh-HK/news/283385664.md)